Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is …
Biotechnology
CA, Burnaby [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Xenon Pharmaceuticals Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | 4.1100 | -0.990 | 28 | 16 | 13 | -66 | 12 | -10 | 5 | -10 | 5 | 25 |
| 2016 | -1.1000 | -1.528 | 15 | 1 | -15 | -102 | -9 | -1 | -12 | -1 | 9 | 2 |
| 2017 | -1.4800 | -1.487 | 1 | 12 | -22 | -99 | -25 | -7 | -25 | -7 | 6 | 19 |
| 2019 | -1.7800 | -1.630 | 0 | 3 | -34 | -109 | -36 | -2 | -38 | -2 | 8 | 5 |
| 2020 | -1.6000 | -0.871 | 6 | 30 | -41 | -58 | -40 | -17 | -81 | -18 | 10 | 46 |
| 2021 | -0.8300 | -1.658 | 32 | 20 | -28 | -110 | -31 | -12 | -81 | -12 | 12 | 31 |
| 2022 | -1.8100 | -2.086 | 18 | 12 | -78 | -139 | -78 | -7 | -154 | -7 | 21 | 18 |
| 2023 | -2.0700 | -2.827 | 9 | 2 | -125 | -185 | -129 | -1 | -234 | -1 | 32 | 3 |
| 2024 | -2.7300 | -3.082 | 0 | 0.31 | -182 | -206 | -210 | 0.19 | -214 | 0.19 | 43 | 0.48 |
| 2025 | - | -3.556 | - | 5 | - | -221 | - | -3 | - | -3 | - | 8 |
| 2026 | - | -3.818 | - | 43 | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | -2.222 | - | 245 | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 0.355 | - | 533 | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-38.104% $15.68 · MISS
Nov. 6, 2024Price Then
$43.33
Price Target
$56.83
Price Now
$41.15